Retatrutide 10mg

1. What is Retatrutide?

Retatrutide is an investigational triple hormone receptor agonist that targets the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Developed for the treatment of obesity and type 2 diabetes, Retatrutide represents a next-generation incretin-based therapy aimed at maximizing metabolic benefits such as weight loss, improved glycemic control, and lipid regulation.

2. Retatrutide Structure

Sequence:YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3

Molecular Formula:C221H342N46O68

Molecular Weight: 4731.33 g/mol

PubChem SlD: 474492335

CAS Number:2381089-83-2

Synonyms:LY-3437943,NOP2Y096GV

3. Retatrutide Research

Retatrutide is a cutting-edge triagonist peptide targeting three key metabolic receptors: GLP-1, GIP, and glucagon receptors. This multi-pathway approach enables profound appetite suppression, fat metabolism activation, and improved glucose regulation—positioning it as a highly promising therapeutic for obesity and metabolic disorders.

【1】Mechanisms of Action

GLP-1 receptor agonism helps control appetite and slows gastric emptying, improving postprandial glucose control.

GIP receptor activation improves insulin secretion and may enhance pancreatic β-cell function.

Glucagon receptor stimulation boosts energy expenditure and facilitates lipid oxidation, contributing to significant fat loss

This synergistic activation leads to a comprehensive remodeling of metabolic processes, setting Retatrutide apart from single- or dual-pathway incretin agents.

【2】Key Clinical Findings

Body Weight Reduction: In a pivotal placebo-controlled study, Retatrutide induced average weight loss of up to 24.2% at 48 weeks in individuals with obesity but no diabetes

Liver Fat Clearance: In metabolic dysfunction–associated steatotic liver disease (MASLD), up to 93% of participants achieved normalization of liver fat content, with an 82% reduction at 24 weeks
【https://www.nature.com/articles/s41591-024-03018-2】

Insulin Sensitivity: Improvement in HOMA-IR, fasting insulin, and HbA1c were consistently observed across all dosing levels

【3】 Additional Benefits

Triglycerides: Retatrutide lowered serum triglycerides by over 40% in high responders

Adipokines: Favorable shifts in leptin, adiponectin, and βhydroxybutyrate

Visceral & Subcutaneous Fat: Both compartments showed substantial reductions under MRI observation

✅ Why Consider Retatrutide?

💥 Superior weight-loss efficacy compared to existing GLP-1 or GIP agents

🧠 Central and peripheral action: appetite suppression + increased energy use

🔬 Triagonist model: activates 3 metabolic axes for maximal fat oxidation and hormonal balance

🩺 Liver and cardiovascular benefits: Reduces visceral fat, triglycerides, and liver steatosis

🌐 Potential applicability to obesity, T2D, MASLD/NASH, and cardiometabolic syndrome

4. Future Retatrutide Research

A. Long-Term Safety & Durability Studies

Assessing the maintenance of weight loss after treatment cessation

Longitudinal monitoring of cardiovascular markers, adrenal hormones, and hepatic enzymes

B. Head-to-Head Comparisons

Evaluating efficacy versus semaglutide, tirzepatide, and other dual agonists

Defining the ideal patient phenotype for triagonist therapy

C. Renal Function & Diabetic Nephropathy

New trials underway to examine kidney protection potential in obese and insulin-resistant populations

D. Non-Diabetic Applications

Studying effects in prediabetic, normoglycemic obese, and older adult groups

Application in PCOS, sleep apnea, and lipodystrophy syndromes

E. Novel Formulations

Oral peptide systems, microneedle patches, and slow-release injectables are being explored to increase compliance and absorption

F. Precision Dosing Models

Developing AI-based models to individualize dose titration based on fat distribution, insulin resistance, or liver biomarkers

5. Application Areas

✅ Summary

Retatrutide represents a major advancement in metabolic peptide therapeutics. By simultaneously activating the GLP-1, GIP, and glucagon receptors, it delivers unprecedented weight loss, improved insulin sensitivity, and powerful liver-fat clearance—without relying on any single hormonal pathway. With broad indications spanning from obesity to MASLD and metabolic syndrome, Retatrutide is fast becoming one of the most promising agents in the fight against modern metabolic disease.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.